

INDEX

A

- Absenteeism, 89
- Abstinence duration
 - atherosclerosis severity, 199–200
 - bladder cancer, 164
 - cerebrovascular disease, 252–258
 - COPD mortality, 345
 - classifying smoking status, 26–27
 - CHD mortality, 205–215, 223
 - disease development, 129
 - educational attainment, 606–608
 - laryngeal cancer, 131–132
 - locus of control, 542
 - lung cancer diagnosis, 129–131
 - lung cancer risk patterns, 110–122, 122–126
 - multistage models, 126–128
 - MI risk, 203–204
 - overall mortality, 78–80
 - relapse, 23–24, 595–598
 - respiratory symptoms, 303
 - self-efficacy, 541
 - smoking continuum, 606–607
 - withdrawal symptoms, 529–530
- Abstinence
 - long-term, 595–598
 - performance, 525–526
- Age at cessation, lung cancer, 125–126
- Age factors
 - abstinence duration, 606–608
 - airway responsiveness, 338–340
 - cerebrovascular disease, 251
 - CHD mortality, 215–216, 223
 - FEV₁ decline, 329–333
 - menopause, 396–400
 - overall mortality, 80
 - quit ratio, 593–594
 - respiratory symptoms, 286, 288–296
 - smoking and cessation during pregnancy, 390–393
 - smoking continuum, 599–608
- Airway histopathology, former smokers, 108–109
- Airway responsiveness
 - age factors, 338–340
 - clinical studies, 340–341
 - cross-sectional studies, 338–339
 - longitudinal studies, 339–340
 - mechanisms, 338
 - smoking and cessation, 337–341
- Airways obstruction, see FEV₁
- Alcohol consumption
 - cessation, 524–525
 - esophageal cancer, 152–155
 - former smokers, 556–559
 - hepatocellular cancer, 176
 - laryngeal cancer, 132

oral cancer, 151–152
pancreatic cancer, 155–159
American Cancer Society Cancer
Prevention Study-I, 26, 48–49,
75–78, 110, 124, 128, 250, 308,
432, 595–596
American Cancer Society Cancer
Prevention Study-II, 48, 78–79,
110, 124, 129, 132, 159, 172,
215, 241, 245, 250, 252, 258,
308, 345
Anal cancer, 172–176
Analytic issues of consequence
assessment, 55–57
Anxiety, 533–541
Aortic aneurysm, 241
Arrhythmias, 195
Arteriosclerosis obliterans, 244
Assessing smoking cessation, see
Chapter 2
Asthma (see also Airway
responsiveness)
nosology, 279–280
respiratory symptoms, 286
Atherosclerosis
CHD development, 191–193
severity, 199–200
Attributable risk, pregnancy outcome,
393–395

B

Behavioral consequences of cessation,
see Chapter 11
Behavioral measures, 25–31
Bias, 46, 48, 52–55
Biochemical markers, 33–37
Birthweight
cessation after conception, 383–387

cessation before conception,
382–383
continued smoking, 381–382
low, attributable risk, 393–395
smoking and cessation, 379–387
Bladder cancer, 159–165
Blood oxygen delivery, CHD
development, 195–196
Body fat distribution, 495
Body weight, see Chapter 10
Bogus pipeline, 37
Bone loss, see Osteoporosis
Bone mineral content, 444–449
Breast cancer, 169
Breathlessness, see Respiratory
symptoms
British Physicians Study, 79, 110, 128,
205, 308, 341
Bronchitis (see also Respiratory
infections)
mortality, 342–345
nosology, 279

C

Caffeine use, cessation, 524–525
Cancers, nonrespiratory, see Chapter 5:
see also specific sites
Cancers, respiratory, see Chapter 4: see
also specific sites
Carbon monoxide, 34–35
Cardiovascular disease risk, estimated
cessation effects, 197
Cardiovascular diseases, see Chapter 6
Carotid artery plaques, 246
Case–control study design, 49–50
Cerebral blood flow, 246, 251
Cerebrovascular disease
abstinence duration, 252–258

- age factors, 251
- case-control studies, 246–249
- cross-sectional studies, 246
- development, 196
- intervention studies, 251
- oral contraceptives, 258–260
- prospective cohort studies, 249–250
- smoking and cessation, 245–260
- smoking history, 251–252
- summary of observational studies, 251
- Cervical cancer, 165–169
- Cessation
 - consequences assessment, 46–57
 - process and behavior assessment, 22–46
 - rate, see Quit ratio
 - stage model, 22–24
 - time trends, pregnancy, 393
 - timing, birthweight, 382–386
- Chapter conclusions, 9–14
- Chronic obstructive pulmonary disease
 - FEV₁ decline, 328–333
 - mortality, 341–348
 - nosology, 279–285
 - patients, 345–348
- Cigar smoking
 - as cigarette replacement, 555–556
 - lung cancer, 124–125
 - trends, 593
- Cigarette consumption
 - bladder cancer, 164
 - cerebrovascular disease, 251–252
 - FEV₁ decline, 329–333
 - laryngeal cancer, 132
 - lung cancer, 124
 - MI risk, 203
 - oral cancer, 151–152
 - overall mortality, 78–80, 86
 - pancreatic cancer, 155
 - pregnancy, 390–393
 - weight gain, 501–502
- Cohort study design, 48–49
- Conclusions
 - chapter, 9–14
 - volume, 8
- Contextual issues, biochemical
 - assessment, 37–46
- Coping skills, 543–544
- Coronary artery spasm, CHD
 - development, 195
- Coronary heart disease (CHD)
 - cross-sectional studies, 199–200
 - cessation, 197–240
 - development, 191–196
 - mortality, 205–224, 227–229
 - patients, 229–239
 - risk factors, 497–499
- Cotinine, 36–37
- Cough, see Respiratory symptoms
- Craving, 523–524
- Cross-sectional study design, 47–48

D

- D-fenfluramine, weight control, 503–504
- Demographic factors
 - pregnancy outcomes, attributable risk, 393–395
 - smoking and cessation during pregnancy, 390–393
- Depression, 533–541
- Diabetics, CHD mortality, 221–222
- Diet, 500–502
- Dietary changes, 484–486
- Dietary practices, 554–555

Diffusing capacity, former smokers, 327–328
Disease development, abstinence duration, 129
DNA adduct levels, 109–110
Duodenal ulcers (see also Peptic ulcers)
 healing, 432–433
 recurrence, 433–439
Duration of abstinence, see Abstinence duration
Dyspnea, see Respiratory symptoms

E

Ecologic study design, 47
Ectopic pregnancy, 375–376
Educational attainment
 abstinence duration, 606–608
 quit ratio, 595
 smoking continuum, 599–608
Emphysema
 mortality, 342–345
 nosology, 279
Endometrial cancer, 169–172
Energy expenditure, 487–490
Enhancement models, performance, 525–526
Esophageal cancer, 152–155
Estrogen metabolism
 osteoporotic fractures, 443–444
 premature menopause, 398
Ethnic factors
 abstinence duration, 606–608
 quit ratio, 593
 smoking and cessation during pregnancy, 391–393
 smoking continuum, 599–608
Ex-smokers, see Former smokers

F

Fertility
 female, 372, 374–375
 male, 404–409
Fetal growth, 373, 379–387; see also Birthweight
Fetal mortality, 376–379
Forced expiratory volume in 1 second (FEV₁)
 cross-sectional population studies, 308–316
 decline, 328–337, 345–347
 longitudinal population studies, 328–337
Fibrinogens, former smokers, 194
Food intake, 484–486
Former smokers
 absenteeism, 89
 anal cancer, 172–176
 atherosclerosis severity, 199–200
 bladder cancer, 164
 breast cancer, 169
 cerebrovascular disease, 246–260
 cervical cancer, 166–169
 dietary practices, 554–555
 diffusing capacity, 327–328
 early menopause risk, 398–400
 endometrial cancer, 169–172
 esophageal cancer, 152–155
 established COPD, 345–348
 fibrinogen levels, 194
 health practices, 546–561
 health screening, 561–564
 health status, 87–91
 hepatocellular cancer, 176
 HDL-C levels, 192–193
 kidney cancer, 172

leukemia, 176
lung cancer risk patterns, 110–122
medical care utilization, 87
MI survival, 200–224
oral cancer, 147–152
ovarian cancer, 172
overall mortality, 78–80
penile cancer, 172–176
physical activity, 551–554
population percentage, 585
pulmonary function, 308–337
respiratory symptoms, 285–305
stomach cancer, 176
Fractures, *see* Osteoporosis
Framingham Heart Study, 80,
218–221, 230–235, 250, 258,
453, 497–498
Frequency issues, self-reports, 27–28

G

Gastric secretion, smoking, 429–430
Gastric ulcers (*see also* Peptic ulcers)
healing, 440
recurrence, 440–441
Gastrointestinal physiology, smoking,
429–430
Gender factors
abstinence duration, 606–608
alcohol consumption, 556–559
bladder cancer, 164
diet, 485–486
dietary practices, 554–555
esophageal cancer, 152–155
MI survival, 237
oral cancer, 147
overall mortality, 80
pancreatic cancer, 155
physical activity, 551–554

pipe or cigar smoking, 555–556
postcessation weight gain, 473–483
quit ratio, 588–593
respiratory symptoms, 288–296,
303–304
smoking continuum, 599–608
Gestational duration, 379–387; *see also*
Birthweight

H

Health practices, former smokers,
546–561
Health risk changes, 497–500
Health screening, former smokers,
561–564
Health status, 87–91
Hemorrhagic stroke, *see*
Cerebrovascular disease
Hepatocellular cancer, 176
High-density lipoprotein cholesterol
(HDL-C) levels, former smokers,
192–193
Hormones, male reproduction, 401

I

Immune system, respiratory infections,
305–308
Impotence, male, 402–404
Infertility
female, 372, 374–375
male, 405–409
Influenza, *see* Respiratory infections
Inhalation practices, lung cancer, 124
Intention to smoke, 588, 608–609
Intermittent claudication, 243–244
Interpersonal interactions, 545–546
Intervention trials, study design, 50–51
Interviews, 25–29

Ischemic stroke. *see* Cerebrovascular disease

K

Kidney cancer. 172

L

Laryngeal cancer. 131–132

Leukemia. 176

Locus of control. 542–543

Long-term psychological and behavioral consequences and correlates. 532–546

Lung cancer

abstinence duration. 110–122,

122–126, 126–128

age at cessation. 125–126

airway histopathology. 108–109

smoking and cessation. 107–131

cigar smokers. 125

cigarette consumption. 124

DNA adduct levels. 109–110

diagnosis. 129–131

inhalation practices. 124

multistage models. 126–128

nonfilter cigarettes. 124–125

pathophysiologic mechanisms of smoking. 107–110

pipe smokers. 125

smoking duration. 122–123

smoking history. 122–126

M

Major conclusions. 8

Measures of cessation. 22–46

Measures of quitting behavior. 584–588

Medical care utilization. 87

Menopause, premature. 396–400

Metabolic rate. 487–490

Methodologic issues of consequence assessment. 51–57

Methodologies, cessation assessment. *see* Chapter 2

Misclassification of smoking status. 49, 51, 52–55

Mood. 533–541

Morbidity (*see also* Chapter 3: specific causes)

peptic ulcers. 431–432

respiratory. 285–308

Mortality (*see also* Chapter 3: specific causes)

bronchitis. 342–345

COPD. 341–345, 347–348

cohort studies. 75–83

emphysema. 342–345

fetal, neonatal, and perinatal. 374, 376–379

overall, intervention studies. 84–86

peptic ulcers. 432

weight. 491–495

Mouth cancer. *see* Oral cancer

Multiple health habits. 559–561

Multiple primary cancers. 176–177

Multiple Risk Factor Intervention Trial. 24, 28, 50–51, 53, 86, 227–228, 333–335, 495, 498, 560–561, 595

Multistage models, lung cancer. 126–128

Myocardial infarct (MI) risk

case–control studies. 200–204

cigarette consumption. 203

cohort studies. 205–224

healthy persons. 200–229

intervention trials, 224–229
MI patients, 229–239
recurrent, 230–239

N

National Health and Nutrition
Examination Survey, 24, 30, 431,
453, 583–584
National Health Interview Survey, 25,
390–391, 547–564, 583–584
National trends in smoking cessation,
see Appendix
Neonatal mortality, 379–381
Neoplasms, see Cancers; see also
specific sites
Nicotine polacrilex gum
weight control, 502–504
withdrawal symptoms, 528, 539
Nicotine withdrawal, 521–532
Nonbehavioral measures, 31–46
Nonfilter cigarettes, lung cancer,
124–125

O

Obesity, 490–497
Obstructive airways diseases, see
Chapter 7
Occupational factors, respiratory
symptoms, 296–299
Oral cancer
alcohol consumption, 151–152
cigarette consumption, 151–152
former smokers, 147–152
gender factors, 147
smoking and cessation, 147–152
Oral contraceptives, cerebrovascular
disease, 258–260
Osteoporosis, 443–453

Osteoporotic fractures, 449–453
Ovarian cancer, 172
Overweight, adverse medical and
psychosocial outcomes, 490–497

P

Pancreatic cancer, 155–159
Pathophysiologic mechanisms of
smoking
cardiovascular diseases, 191–197
laryngeal cancer, 131
lung cancer, 107–110
male reproduction, 400–401
pregnancy, 371–374
premature menopause, 396–398
osteoporosis, 443–444
respiratory diseases, 279–285
skin wrinkling, 453–456
Penile cancer, 172–176
Peptic ulcer disease, 429–442
Peptic ulcers
morbidity, 431–432
mortality, 432
Performance, abstinence, 525–526, 530
Perinatal mortality
attributable risk, 393–395
smoking and cessation, 376–379
Peripheral arterial occlusive disease,
241–244
Peripheral artery disease
development, 196, 243
prognosis, 243–244
Phenylpropanolamine, weight control,
503–504
Phlegm production, see Respiratory
symptoms
Physical activity, 486, 551–554
Physician advice, 588, 609

Physiologic measures, 32
Pipe smoking
 as cigarette replacement, 555–556
 lung cancer, 124–125
 trends, 593
Pneumonia, see Respiratory infections
Preeclampsia, 387
Pregnancy
 complications, 387
 outcome, 371–395
 prevalence of smoking and
 cessation, 390–393
 time trends in smoking and
 cessation, 393
 weight gain, 373
Prematurity, 386–387
Preterm delivery, 386–387, 395
Prevalence of smoking, pregnancy,
 390–393
Process of smoking behavior change,
 22–24
Psychological effects of cessation, see
 Chapter 11
Pulmonary function
 former smokers, 308–337
 smoking cessation, 316–328

Q

Questionnaires, 25–29
Quit attempts, 606
Quit ratio
 age trends, 593–594
 definition, 585,
 educational trends, 595
 gender trends, 588–593
 racial trends, 593
Quitting behavior, measures, 584–588

R

Racial factors, see Ethnic factors
Recidivism, 595–598; see also Relapse
Reduction of smoking, pregnancy,
 387–389
Relapse, 23–24, 530–531, 595–598
Report
 conclusions, 8
 development, 8–9
 overview, 5–7
Reproduction
 female, 371–400
 male, 400–409
Reproduction, see Chapter 8
Respiratory cancers, see Chapter 4
Respiratory diseases, see Chapter 7
Respiratory function tests, see
 Spirometric parameters; Small
 airways function
Respiratory infections, 305–308
Respiratory morbidity, smoking
 cessation, 285–308
Respiratory symptoms
 abstinence duration, 303
 asthmatics, 286
 cessation clinics, 285–287
 cross-sectional population studies,
 288–296
 longitudinal studies, 299–305
 occupational groups, 296–299
 reversal, possible mechanisms, 304
 smoking and cessation, 285–305
 smoking history, 299–303

S

Self-efficacy, 541–542
Self-management skills, 543–544

Self-report measures, 25–29
 Self-monitoring, 29
 Sexual activity, male, 401–404
 Sexual behavior, cervical cancer, 166
 Shortness of breath, *see* Respiratory symptoms
 Skin wrinkling, 453–456
 Small airways function, smoking cessation, 323–327
 Smoking and cessation surveys, methodology, 583–584
 Smoking behavior change, 22–24
 Smoking characteristics, *see* Inhalation practices
 Smoking continuum
 abstainers for less than 1 year, 606
 abstainers for 1 to 4 years, 606–607
 abstainers for 5 years, 607
 definition, 585–588
 smokers never trying to quit, 599
 smokers quitting for at least 1 day during 12-month period, 606
 Smoking duration, lung cancer, 122–123
 Smoking history
 cerebrovascular disease, 251–252
 FEV₁, 308–316, 328–337
 lung cancer, 122–126, 126–128
 respiratory symptoms, 299–303
 Smoking interventions
 cerebrovascular disease, 251
 CHD mortality, 224–229
 overall mortality, 84–86
 pregnancy, 387–389
 weight control, 500–502
 Social support, 545–546
 Spasm, coronary artery, 195
 Sperm quality, 404–409
 Spirometric parameters, smoking cessation, 319–323
 Spontaneous abortion, 372, 376
 Statistical considerations, 52
 Stomach cancer, 176
 Stress, 533–541
 Stroke patients, cessation, 260
 Study design, 46–51
 Subarachnoid hemorrhage, 249, 250, 258–260
 Surrogate assessments, 30–31
 Survival prognosis
 lung cancer, 129–131
 MI patients, 230–239

T

T lymphocytes, 306–307
 Temporal issues, self-reports, 27–28
 Terminology, assessment, 33–34
 Thiocyanate, 35–36
 Thrombosis, CHD development, 193–195
 Time trends in smoking and cessation, pregnancy, 393
 Tobacco consumption, esophageal cancer, 152–154
 Tracheal mucous velocity, 304

U

U.S. Veterans Study, 49, 79, 110, 124, 125, 128, 129, 132, 151, 152, 155, 164, 172–176, 217–218, 251–252, 345, 432
 Ulcer healing and recurrence, 432–441
 Ulcer occurrence, 429–432
 Ulcers, *see also* Peptic ulcers: Gastric ulcers; Duodenal ulcers

V

Volume conclusions, 8

W

Weight control strategies, 500–504

Weight cycling, 492–495

Weight gain (see also Chapter 10)

pregnancy, 373

risk and amount, 473–483

causes, 483–490

Weight, mortality, 491–495

Weight-related health risks, 497–500

Well-being, psychological, 533–541

Wheeze, see Respiratory symptoms

Withdrawal symptoms

relapse, 530–531

relief, performance, 525–526

timecourse, 521, 529–530

variability, 526–529

Wrinkling, skin, 453–456

540
530